SCHEMBL13719376

SCHEMBL13719376

CC(C)Cc1ccc(Oc2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.49
PPARG P37231 1/20 0.49
PPARA Q07869 1/20 0.49
HTR2A P28223 2/20 0.49
HTR2B P41595 2/20 0.49
HTR2C P28335 1/20 0.49
CETP P11597 1/20 0.45
MAPK14 Q16539 1/20 0.44
SIGMAR1 Q99720 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
ADRA2C P18825 1/20 0.43
SLC6A4 P31645 1/20 0.43
ADRA1A P35348 1/20 0.43
DRD3 P35462 1/20 0.43
OPRK1 P41145 1/20 0.43
KIF11 P52732 1/20 0.43
MAOB P27338 1/20 0.43
FFAR1 O14842 1/20 0.42
FDFT1 P37268 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13719227 0.90 HTR2A (0.58) LTA4HPPARGPPARAHTR2AHTR2B
SCHEMBL13719230 0.84 ALDH1A1 (0.46) LTA4HPPARGPPARAMAPK14MAOB
SCHEMBL19841911 0.84 MAOB (0.53) PPARGPPARAHTR2AHTR2BHTR2C
SCHEMBL12603801 0.83 LTA4H (0.52) LTA4HPPARGPPARAMAPK14MAPT
SCHEMBL27579381 0.82 LTA4H (0.59) LTA4HMAPK14MAPTKIF11L3MBTL1
SCHEMBL921317 0.81 MAOB (0.61) LTA4HMAPK14KIF11MAOBL3MBTL1
SCHEMBL18713541 0.81 FFAR1 (0.49) LTA4HPPARGPPARACETPMAPT
Hydrochloric Acid SCHEMBL17136566 0.80 MAOB (0.64) LTA4HMAPK14KIF11MAOB
SCHEMBL875576 0.80 LTA4H (0.58) LTA4HPPARGPPARAMAPK14KIF11
SCHEMBL12868961 0.80 LTA4H (0.49) LTA4HPPARGCETPMAPTKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579479-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-25 US disclosed
US-7241780-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOLS-MYERS SQUIBB COMPANY (US) 2007-07-10 US disclosed
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method GPR119, LIPC, ACACA LTA4H 3219/4885PPARG 65/4885PPARA 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.